Tokai Pharmaceuticals (TKAI) Appoints Gerald Quirk As General Counsel And Executive Vice President, Business Operations

BOSTON--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the appointment of Gerald Quirk as General Counsel and Executive Vice President, Business Operations. Mr. Quirk brings to Tokai more than twenty years of experience advancing the legal and business interests of public biopharmaceutical companies, including the development and commercialization of oncology products.

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Nodthera bagged $55 million to get its lead asset through phase 1 and into proof-of-concept studies, and a second program into the clinic.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.